Overstated Therapeutic Progress: Management materially overstated the developmental progress and commercial prospects of its prostate cancer therapeutic candidates, specifically TLX591 and TLX592.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback